South Korea Army Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2015
NCT02440204
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Armed Forces Capital Hospital, Republic of Korea | Armed Forces Hampyeong Hostpital

Active Ingredients

Drugs in Phase 4 Trials (3)

celecoxib (celebrex) (1 trial)

ropivacaine (naropin) (1 trial)

sodium chloride (1 trial)

Drugs in Other Trials (2)

remifentanil (ultiva) (1 trial)

sevoflurane (ultane) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Emergence Delirium (Phase 4)

Psychomotor Agitation (Phase 4)

Spondylarthritis (Phase 4)

Spondylarthropathies (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5